Kerala, India

Parameswaran Makrishnan

This inventor holds 1 USPTO granted patent. Top assignee: Yeda Research and Develpment & Co. Ltd. Active years: 2012.


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Parameswaran Makrishnan: Innovator in Pharmaceutical Compositions

Introduction

Parameswaran Makrishnan is a notable inventor based in Kerala, India. He has made significant contributions to the field of pharmaceuticals, particularly in developing methods for treating diseases associated with NF-κB activity. His innovative approach has the potential to impact many lives positively.

Latest Patents

Makrishnan holds 1 patent for his work titled "Pharmaceutical compositions for treating diseases associated with NF-κB activity." This patent outlines a method of treating diseases by providing a therapeutically effective amount of an agent capable of modulating NIK-HC8 binding. This innovative method showcases his commitment to advancing medical science.

Career Highlights

Currently, Parameswaran Makrishnan is associated with Yeda Research and Development Co. Ltd. His role in this esteemed organization allows him to further his research and development efforts in the pharmaceutical sector. His work is characterized by a dedication to improving therapeutic options for patients.

Collaborations

Throughout his career, Makrishnan has collaborated with esteemed colleagues, including David Wallach and Taisa Shmushkovich. These collaborations have enriched his research and contributed to the advancement of pharmaceutical sciences.

Conclusion

Parameswaran Makrishnan is a distinguished inventor whose work in pharmaceutical compositions demonstrates his innovative spirit and dedication to improving healthcare. His contributions are paving the way for new treatments that could benefit many individuals suffering from diseases linked to NF-κB activity.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…